On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Stratec Biomedical AG Gemini. This instrumentation change is necessary as Bio-Rad is discontinuing service on our existing QuickStep instrumentation.
Although the Immucor assay and sample requirements will remain the same, the package insert has been modified to state the assay is specific to the Stratec Gemini instrument. The new package insert, assay history list, and platform history list will be available on the CTS website on 04/29/19.
Reminder - Five CTS Forms will be updated on Monday September 2, 2019. Some of the forms are posted ...
At CTS, we understand the impact converting to the Ortho viral marker platform has on your operation...
Through communications with our clients, CTS is aware of the current national blood shortage. We rea...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
We have now added a new section called the "Assay History List" to the "At A Gla...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...